Omeros Reports Q1 2026 Earnings with Strong Performance from YARTEMLEA

Omeros (OMER) reported first-quarter earnings for 2026, highlighting strong performance driven by the launch of its lead MASP-2 inhibitor, YARTEMLEA. The drug generated $11.1 million in gross revenues and became cash flow positive within a quarter despite launching mid-January.

By Motley Fool Transcribing, The Motley Fool Thu, May 14, 2026 at 6:14 PM GMT+3 27 min read · Yahoo Finance · May 14, 2026, 15:14 UTC

Omeros Reports Q1 2026 Earnings with Strong Performance from YARTEMLEA

Tickers: $NVO $OMER

Topics: complement inhibitors pharmaceuticals TA-TMA treatment

Read the full article at Yahoo Finance

More World news

Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC
Rising New Vehicle Monthly Payments Pose Affordability Risks for Ford and General Motors Motley Fool · November 12, 2026, 16:33 UTC
SpaceX Shares Rise Following Nvidia CEO Jensen Huang Resignation Motley Fool · November 12, 2026, 16:34 UTC
tZERO Receives CFTC Approval for Derivatives Exchange and Clearing Operations PR Newswire · November 12, 2026, 16:36 UTC
enGene Therapeutics Shares Surge Following Positive Mid-Stage Trial Data and Piper Sandler Upgrade Seeking Alpha · November 12, 2026, 16:33 UTC
Former Nvidia CEO Jensen Huang to Testify Before Congress Regarding Export Controls and Security Concerns TechCrunch · November 12, 2026, 16:36 UTC
Nobu Hospitality and Infracorp Partner to Develop Luxury Destination in Bahrain PR Newswire · November 12, 2026, 16:34 UTC
Serco Group Announces $292 Million Acquisition of QinetiQ's U.S. Business Seeking Alpha · November 12, 2026, 16:30 UTC
Ag Growth International Targets $30M in Cost Savings Amid Divergent Business Performance Seeking Alpha · November 12, 2026, 16:30 UTC
Qualstar Reports Q3 Non-GAAP EPS of $0.09 and Revenue of $2.04 Million Seeking Alpha · November 12, 2026, 16:31 UTC